Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFMW) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Sunshine Biopharma (SBFMW) over the last 9 years, with Q3 2025 value amounting to 11.54%.

  • Sunshine Biopharma's EBIT Margin rose 15800.0% to 11.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.35%, marking a year-over-year decrease of 24400.0%. This contributed to the annual value of 16.67% for FY2024, which is 32000.0% up from last year.
  • Sunshine Biopharma's EBIT Margin amounted to 11.54% in Q3 2025, which was up 15800.0% from 21.83% recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EBIT Margin peaked at 11.54% during Q3 2025, and registered a low of 3184.5% during Q1 2021.
  • Over the past 5 years, Sunshine Biopharma's median EBIT Margin value was 21.83% (recorded in 2025), while the average stood at 462.0%.
  • As far as peak fluctuations go, Sunshine Biopharma's EBIT Margin plummeted by -28449300bps in 2021, and later skyrocketed by 21870100bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBIT Margin (Quarter) stood at 328.52% in 2021, then tumbled by -81bps to 593.01% in 2022, then skyrocketed by 97bps to 15.46% in 2023, then tumbled by -37bps to 21.24% in 2024, then surged by 46bps to 11.54% in 2025.
  • Its EBIT Margin stands at 11.54% for Q3 2025, versus 21.83% for Q2 2025 and 14.56% for Q1 2025.